Arctic Bioscience - Board approval of share capital increase related to conversion of debt

08 May 2025 18:50 CEST

Reference is made to the stock exchange release published by Arctic Bioscience
28th April 2025 regarding exercise of right to convert debt and corresponding
issuance of new shares in Arctic Bioscience.

On 8 May 2025, the Board of Arctic Bioscience, on the basis of a board
authorization granted by the Company's General Meeting on 26[th] April 2024,
resolved to increase the share capital from NOK 2 668 934 to NOK 2 685 934 by
issuance of 170 000 new shares with a nominal value of NOK 0,10 per share, at a
subscription price of NOK 3 per share, including a share premium of NOK 2,90 per
share.

The total amount allocated as share premium is NOK 493 000. The total
subscription amount is NOK 510 000. Following the registration of this share
capital increase in the Norwegian Register of Business Enterprises, the
Company's share capital will be NOK 2 685 934 divided into 26 859 340 shares,
each having a nominal value of NOK 0,10.

Minutes from Board Meeting and statement regarding capital increase are attached
hereto.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Act.

For more information, please contact:

Christer L. Valderhaug

CEO

Phone: +47 920 84 601

E-mail: christer@arctic-bioscience.com

About Arctic Bioscience

Arctic Bioscience is a biotech company developing and commercializing
pharmaceutical and nutraceutical products based on unique bioactive marine
compounds.

The company is developing HRO350 - a novel oral drug candidate. HRO350 is being
developed for treatment of patients with mild-to-moderate psoriasis. This is a
large patient group in need of new effective medicines with beneficial safety
profile.

Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as
well as finished goods under the ROMEGA® brand.

Arctic Bioscience is led by a highly skilled team of talents with diverse and
highly relevant background.

More information:
Access the news on Oslo Bors NewsWeb site

645834_20250508_Minutes_from_Board_Meeting.pdf
645834_20250508_Statement_from_the_BoD_of_ABS.pdf